CNN released a report examining an analysis of the Parkinson’s drug, Nuplzaid by the nonprofit Institute for Safe Medication Practices. The report said within one year after approval the FDA received 244 death reports, however now, that number seems to be close to 700. Nuplzaid manufacturer, Acadia believes that their drug’s purpose outweighs the side effects.
Approved by the FDA in 2016, Nuplazid, manufactured by Acadia, is a selective serotonin inverse agonist that targets 5-HT2A receptors for hallucinations and delusions associated with Parkinson’s disease psychosis. The FDA sped the approval up after pressure that this drug is the first of its kind. In 2012, Congress created this designation after the criticism that the process could be too slow. This is especially important when the drug’s potential benefits outweighed its risks for its intended patients. Some FDA officials concluded that Nuplazid’s public health benefit was enough to merit approval of the drug since Acadia estimated that 40% of the four to six million people worldwide with Parkinson’s suffer from psychosis.
In April 2018, CNN released a report examining an analysis by the nonprofit Institute for Safe Medication Practices. The report said within one year after approval the FDA received 244 death reports. Not only did the nonprofit organization’s report link Nuplazid to the deaths, it questioned its efficacy as a psychosis treatment. In fact, the same organization since publishing their findings in June 2017 has said deaths have risen to over 700.
Shortly after the drug’s release, family members, doctors, and other healthcare professionals started reporting adverse events after using the medication. These include deaths, life-threatening incidents, falls, insomnia, nausea, and fatigue. Plus, in more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid. The very side effect the FDA approved the drug to treat.
We Want to Help Victims
Furthermore, it is your right for manufacturers to inform you about the long-term risks associated with medications, and it is the responsibility of manufacturers to provide this information. If a loved one has died after using Nuplazid, you should demand accountability from Acadia.
Of course, we want to help send a message that this is not acceptable. We are advocates for consumers who have been harmed by dangerous products, and likewise, we have the experience necessary to successfully litigate these cases.
Contact the Michael Brady Lynch Firm today for a free consultation to learn more about seeking justice. Compensation may be available for any medical expenses associated with this ordeal, as well as for your physical and emotional suffering. There is no obligation.